Burden of Generalized myasthenia gravis
1 evidence topic · 13 sources
Summary
The US estimates are for myasthenia gravis as a whole. In 2021 US claims and electronic health records, the diagnosed prevalence was 37.0 per 100,000 persons and the incidence 3.1 per 100,000 persons, and a separate claims analysis estimated approximately 82,715 US adults living with myasthenia gravis in 2021. A global meta-analysis of 63 articles estimated a prevalence of 12.4 (95% CI 10.6 to 14.5) per 100,000 population. Generalized disease specifically was measured in one cohort, where the 2019 prevalence was 11.18 and the incidence 2.95 per 100,000 population. Up to 80% of patients with ocular onset develop generalized symptoms, usually within two years, and approximately one third of patients with generalized disease have an exacerbation in a given year. Among hospitalizations from 2010 to 2019, the in-hospital mortality rate averaged 1.8%, and mortality averaged 5.0% among patients aged 65 years or older; in a separate cohort, 5-year overall survival was 75%, declining to 39% among those with crisis.
Among 841 participants from seven countries, mean baseline EQ-5D-5L utility was 0.817, 0.766, 0.648, and 0.530 for MGFA classes I to IV; in a larger MRW cohort (n = 1859), average EQ-5D-5L utility was 0.739, compared with 0.843 in POPUP. In Komodo Research data from 2017 to 2023, mean annual all-cause total health care costs in adults with newly diagnosed generalized myasthenia gravis were $58,341, compared with $14,469 in the non-MG cohort, with 59.3% of the difference driven by pharmacy costs (mostly immunoglobulin). Annual all-cause costs were $76,381 with any glucocorticoid use and $35,309 without, and mean monthly costs were $17,330 in a subgroup with exacerbation or crisis.